Tags

Type your tag names separated by a space and hit enter

Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
J Antimicrob Chemother 1998; 42(5):665-7JA

Abstract

Because combination therapy is required to treat human toxoplasmosis, we examined combinations of the ketolides HMR 3004 and HMR 3647 with atovaquone, clindamycin or sulphadiazine in a murine model of toxoplasmosis. An oral dose of 50 mg/kg/day of HMR 3004 protected 30% of mice lethally infected with Toxoplasma gondii. The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine. Similar results were noted with 25 mg/kg/day of HMR 3647. These results demonstrate that these drug combinations are highly effective for treating toxoplasmosis in mice.

Authors+Show Affiliations

Research Institute, Palo Alto Medical Foundation, CA, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9848454

Citation

Araujo, F G., et al. "Use of Ketolides in Combination With Other Drugs to Treat Experimental Toxoplasmosis." The Journal of Antimicrobial Chemotherapy, vol. 42, no. 5, 1998, pp. 665-7.
Araujo FG, Khan AA, Bryskier A, et al. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. J Antimicrob Chemother. 1998;42(5):665-7.
Araujo, F. G., Khan, A. A., Bryskier, A., & Remington, J. S. (1998). Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. The Journal of Antimicrobial Chemotherapy, 42(5), pp. 665-7.
Araujo FG, et al. Use of Ketolides in Combination With Other Drugs to Treat Experimental Toxoplasmosis. J Antimicrob Chemother. 1998;42(5):665-7. PubMed PMID: 9848454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. AU - Araujo,F G, AU - Khan,A A, AU - Bryskier,A, AU - Remington,J S, PY - 1998/12/16/pubmed PY - 1998/12/16/medline PY - 1998/12/16/entrez SP - 665 EP - 7 JF - The Journal of antimicrobial chemotherapy JO - J. Antimicrob. Chemother. VL - 42 IS - 5 N2 - Because combination therapy is required to treat human toxoplasmosis, we examined combinations of the ketolides HMR 3004 and HMR 3647 with atovaquone, clindamycin or sulphadiazine in a murine model of toxoplasmosis. An oral dose of 50 mg/kg/day of HMR 3004 protected 30% of mice lethally infected with Toxoplasma gondii. The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine. Similar results were noted with 25 mg/kg/day of HMR 3647. These results demonstrate that these drug combinations are highly effective for treating toxoplasmosis in mice. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/9848454/Use_of_ketolides_in_combination_with_other_drugs_to_treat_experimental_toxoplasmosis_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/42.5.665 DB - PRIME DP - Unbound Medicine ER -